Mitochondrial Medicine – Therapeutic Development
In late November, Abliva will attend the annual scientific conference Mitochondrial Medicine - Therapeutic Development in Hinxton, UK. Abliva's Chief Medical Officer, Magnus Hansson, will present a poster on one of the important preparatory studies for the upcoming, potentially registrational, Phase 2 study, FALCON, with KL1333 in patients with mitochondrial diseases.